Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th

PALO ALTO, Calif. – January 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host one-on-one meetings with investors at the SunTrust Robinson Humphrey 2017 Orphan Drug Day conference on Tuesday, February 14, 2017, at the JW Marriott Essex House in New York City.

About Eiger
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Eiger BioPharmaceuticals

SOURCE Eiger Bio, Inc.
Investors: Andrew McDonald LifeSci Advisors, LLC, 646-597-6987, andrew@lifesciadvisors.com

PDF Icon

Date Title (click to view the full PR) PDF
December 12, 2016 Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) – Positive Interim Data from Phase 2 Multiple-Ascending Dose Study – Novel Liquid Formulation of Exendin 9-39 – US Orphan Designation for Hyperinsulinemic Hypoglycemia PDF Icon
November 29, 2016 Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) – Exendin 9-39 investigational new drug (IND) application filed – PBH Analyst / Key Opinion Leader Event planned December 9th – Multiple-ascending dose (MAD) study interim data to be presented PDF Icon
November 14, 2016 Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting – Update on Data Presented and Analyst Meeting through Monday Evening PDF Icon
November 14, 2016 Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program – Data Presented through Monday Morning PDF Icon
November 8, 2016 Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results PDF Icon
October 24, 2016 Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection – Collaboration with ARUP Laboratories and Hepatitis B Foundation – HDV viral load assay now available in U.S. PDF Icon
October 19, 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PDF Icon
October 17, 2016 Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) PDF Icon
October 13, 2016 Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting PDF Icon
September 7, 2016 Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School PDF Icon
September 6, 2016 Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th PDF Icon
September 1, 2016 Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016 PDF Icon
August 18, 2016 Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PDF Icon
August 17, 2016 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PDF Icon
August 10, 2016 Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results PDF Icon
July 28, 2016 Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation – Raising Awareness of Hepatitis Delta Virus Co-Infection PDF Icon
July 25, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema PDF Icon
July 20, 2016 Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH) PDF Icon
July 18, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension PDF Icon
July 6, 2016 Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th PDF Icon
June 13, 2016 Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia PDF Icon
June 6, 2016 Eiger to Participate in Jefferies 2016 Healthcare Conference PDF Icon
May 10, 2016 Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery PDF Icon
May 3, 2016 Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations PDF Icon
April 20, 2016 Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb PDF Icon
April 4, 2016 Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. “Chuck” Bramlage PDF Icon
March 30, 2016 Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting PDF Icon
March 28, 2016 Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency PDF Icon
March 22, 2016 Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PDF Icon
March 22, 2016 Celladon Announces Results of Special Meeting PDF Icon
March 14, 2016 Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School PDF Icon
March 9, 2016 ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote “FOR” Proposed Merger PDF Icon
February 29, 2016 Eiger to Participate in Cowen & Company 2016 Health Care Conference PDF Icon
February 11, 2016 Celladon Sets Date for Special Meeting of Stockholders PDF Icon
January 19, 2016 Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV – 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 3) Study at National Institutes of Health (NIH) PDF Icon
January 6, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School in Hannover, Germany PDF Icon
Date Title (click to view the full PR) PDF
December 15, 2015 Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension PDF Icon
November 30, 2015 Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension PDF Icon
November 18, 2015 Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement PDF Icon
November 12, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University – Clinical Proof of Concept Data Already Generated in Patients PDF Icon
November 11, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University – Novel Target Identified as Potential Therapeutic Approach for Lymphedema PDF Icon
November 10, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University PDF Icon
November 9, 2015 Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4 – First Clinical Target – Pulmonary Arterial Hypertension (PAH) PDF Icon
October 23, 2015 Eiger BioPharmaceuticals Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of Directors PDF Icon
October 20, 2015 Eiger BioPharmaceuticals Appoints Eduardo Martins, M.D., D.Phil., as Senior Vice President, Liver and Infectious Diseases Drug Development PDF Icon
August 17, 2015 Eiger BioPharmaceuticals Announces Key Operational Hires to Senior Management Team: Jim Welch, Chief Financial Officer & Jim Shaffer, Chief Business Officer PDF Icon
July 20, 2015 The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus (HDV) Infected Patients PDF Icon
April 28, 2015 Eiger BioPharmaceuticals Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) PDF Icon
April 20, 2015 FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection PDF Icon
April 14, 2015 Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs PDF Icon
April 13, 2015 Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta (HDV) at the European Association for the Study of the Liver Conference – April 22 to 26, 2015 PDF Icon
February 23, 2015 Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) PDF Icon